PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
7 hedge funds and large institutions have $176K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
21% more capital invested
Capital invested by funds: $146K → $176K (+$30K)
0% more funds holding
Funds holding: 7 → 7 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1.09K |
| 2 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$8 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SB
1
Sunflower Bank
Dallas,
Texas
| $163K | – | – | – |
|
|
HFBOT
2
Home Federal Bank of Tennessee
Knoxville,
Tennessee
| $7K | – | – | – |
|
|
LDB
3
Lee, Danner & Bass
Nashville,
Tennessee
| $3K | – | – | – |
|
|
4
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | -$1.09K | -22,257 | -52% |
|
|
AA
5
Ancora Advisors
Cleveland,
Ohio
| $1K | -$8 | -120 | -0.8% |
|
|
ACM
6
Academy Capital Management
Waco,
Texas
| $1K | – | – | – |
|
PVCT Hedge Fund Activity: Q1 2022 in Review
7 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2022, worth a combined $176K — up 21% from $146K a quarter earlier.
Fund positioning in PVCT was balanced in Q1 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was CAPTRUST Financial Advisors, cutting an estimated $1.09K.
- 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $176K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2022, up 21% quarter-over-quarter.
- 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2022 and 0 closed out.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q1 2022 was CAPTRUST Financial Advisors, an estimated $1.09K sold.
Based on aggregated 13F filings for Q1 2022.